Drug Safety

, Volume 6, Issue 3, pp 183–191 | Cite as

Risk-Benefit Assessment of Drugs Used for the Treatment of Menstrual Disorders

  • Jennifer M. Higham
  • Robert W. Shaw
Review Article Risk-Benefit Assessment


This article considers the benign yet debilitating conditions of menorrhagia, dysmenorrhoea and irregular menstrual bleeding. Surprisingly little has been reported in the literature concerning these common ailments which can detract from the quality of female life during the reproduction years. Both dysmenorrhoea and menorrhagia are subjective complaints, but despite accurate means of measuring menstrual blood loss such quantification is rarely performed. This lack of diagnostic accuracy is a cause for concern, especially as both medical and surgical treatment are not without risk.

The therapeutic alternatives which are commonly prescribed in an attempt to rectify such menstrual disorders are discussed. These include the nonsteroidal anti-inflammatory agents, the combined oral contraceptives, danazol, progestogens, antifibrinolytics, haemostatics, luteinising hormone releasing hormone analogues and clomiphene. The results of clinical trials which have utilised these various agents are considered in terms of both the effectiveness of treatment and its potential adverse effects.


Tranexamic Acid Danazol Clomiphene Mefenamic Acid Combine Oral Contraceptive 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Achiron A, Gornish M, Melamed E. Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia. Stroke 21: 817–819, 1990PubMedCrossRefGoogle Scholar
  2. Agnelli G, Gresele P, De Cunto M, Gallai V, Nenci G. Tranexamic acid, IUCD and fatal cerebral arterial thrombosis. British Journal of Obstetrics and Gynaecology 89: 681–682, 1982PubMedCrossRefGoogle Scholar
  3. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstetrica Gynecologica Scandinavica 67: 645–648, 1988CrossRefGoogle Scholar
  4. Bergqvist A, Rybo G. Treatment of menorrhagia with intrauterine release of progesterone. British Journal of Obstetrics and Gynaecology 90: 255–258, 1983PubMedCrossRefGoogle Scholar
  5. Bishop PMF and de Almeida JC. Treatment of functional menstrual disorders with norethisterone. British Medical Journal 1: 1103–1105, 1960PubMedCrossRefGoogle Scholar
  6. Bonnar J, Sheppard BL, Dockeray CJ. The haemostatic system and dysfunctional uterine bleeding. Research and Clinical Forums 5: 27–36, 1983Google Scholar
  7. Cameron IT, Haining RH, Lumsden MA, Thomas VR, Smith SK. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology 76: 85–88, 1990PubMedGoogle Scholar
  8. Cameron IT, Leask R, Kelly RW, Baird DT. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 34: 99–110, 1987PubMedCrossRefGoogle Scholar
  9. Chimbira TH, Anderson AB, Cope E, Turnbull AC. Effect of danazol on serum gonadotrophins and steroid hormone concentrations in women with menorrhagia. British Journal of Obstetrics and Gynaecology 87: 330–336, 1980bPubMedCrossRefGoogle Scholar
  10. Chimbira TH, Anderson AB, Naish C, Cope E, Turnbull AC. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. British Journal of Obstetrics and Gynaecology 87: 1152–1158, 1980aPubMedCrossRefGoogle Scholar
  11. Chimbira TH, Anderson AB, Turnbull AC. Relation between measured menstrual blood loss and patient’s subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. British Journal of Obstetrics and Gynaecology 87: 603–609, 1980cPubMedCrossRefGoogle Scholar
  12. Chimbira TH, Cope E, Anderson AB, Bolton FG. The effect of danazol on menorrhagia, coagulation mechanisms, haemato-logical indices and body weight. British Journal of Obstetrics and Gynaecology 86: 46–50, 1979PubMedCrossRefGoogle Scholar
  13. Cole SK, Billewicz WZ, Thomson AM. Sources of variation in menstrual blood loss. Journal of Obstetrics and Gynaecology in the British Commonwealth 78: 933–939, 1971CrossRefGoogle Scholar
  14. Conyngham RB. Norethisterone in menorrhagia. New Zealand Medical Journal 64: 697–701, 1965Google Scholar
  15. Coulter A, McPherson K, Vessey M. Do British women undergo too many or too few hysterectomies?. Social Sciences and Medicine 27: 987–994, 1988CrossRefGoogle Scholar
  16. Dockeray CJ. The medical treatment of menorrhagia. In Chamberlain (Ed.) Contemporary obstetrics and gynaecology, pp. 299–314, Butterworths, London, 1988Google Scholar
  17. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. British Journal of Obstetrics and Gynaecology 96: 840–844, 1989PubMedCrossRefGoogle Scholar
  18. Foss GL. Clinical experience with norethisterone and norethisterone acetate. British Medical Journal 2: 1187–1191, 1960PubMedCrossRefGoogle Scholar
  19. Fraser IS. The treatment of menorrhagia with mefenamic acid. Research and Clinical Forums 5: 93–99, 1983Google Scholar
  20. Fraser IS. Treatment of dysfunctional uterine bleeding with danazol. Australia and New Zealand Journal of Obstetrics and Gynaecology 25: 224–226, 1985CrossRefGoogle Scholar
  21. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. American Journal of Obstetrics and Gynecology 149: 788–793, 1984PubMedGoogle Scholar
  22. Fraser IS, McCarron G, Markham R, Robinson M, Smyth E. Long-term treatment of menorrhagia with mefenamic acid. Obstetrics and Gynecology 61: 109–112, 1983PubMedGoogle Scholar
  23. Fraser IS, Pearse C, Shearman RP, Elliott PM, McIlveen J, et al. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstetrics and Gynecology 58: 543–551, 1981PubMedGoogle Scholar
  24. Grant JM, Hussein IY. An audit of abdominal hysterectomy over a decade in a district hospital. British Journal of Obstetrics and Gynaecology 91: 73–77, 1984PubMedCrossRefGoogle Scholar
  25. Hagenfeldt K. The role of prostaglandins and allied substances in uterine haemostasis. Contraception 36: 23–35, 1987PubMedCrossRefGoogle Scholar
  26. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss, a population study. Acta Obstetrica et Gynecologica Scan-dinavica 45: 320–351, 1966CrossRefGoogle Scholar
  27. Hallberg L, Nilsson L. Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation 16: 244–248, 1964PubMedCrossRefGoogle Scholar
  28. Harrison RF, Campbell S. A double-blind trial of ethamsylate in the treatment of primary and intrauterine-device menorrhagia. Lancet 2: 283–285, 1976PubMedCrossRefGoogle Scholar
  29. Haynes PJ, Flint AP, Hodgson H, Anderson AB, Dray F, et al. Studies in menorrhagia: (a) mefenamic acid, (b) endometrial prostaglandin concentrations. International Journal of Gynaecology and Obstetrics 17: 567–572, 1980PubMedGoogle Scholar
  30. Jeppsson S, Mellquist P, Rannevik G. Short-term effects of dan-azol on endometrial histology. Acta Obstetrica et Gynecologica Scandinavica 123: (Suppl.) 41–44, 1984CrossRefGoogle Scholar
  31. Loffer FD. Hysteroscopy with selective endometrial sampling compared with D & C for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstetrics and Gynecology 73: 16–20, 1989PubMedGoogle Scholar
  32. Lumsden MA. Dysmenorrhoea. In Baird & Michie (Eds) Mechanism of menstrual bleeding, pp. 195–213, Raven Press, New York, 1985Google Scholar
  33. MacKenzie IZ, Bibby JG. Critical assessment of dilatation and curettage in 1029 women. Lancet 2: 566–568, 1978PubMedCrossRefGoogle Scholar
  34. Makarainen L, Ylikorkala D. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. British Journal of Obstetrics and Gynaecology 93: 974–978,1986PubMedCrossRefGoogle Scholar
  35. Matta WH, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the LHRH analogue buserelin in premenopausal women. Clinical Endocrinology 29: 45–51, 1988PubMedCrossRefGoogle Scholar
  36. Metcalf MG. Incidence of ovulatory cycles in women approaching the menopause. Journal of Biosocial Science 11: 39–48, 1979PubMedCrossRefGoogle Scholar
  37. Mishell Jr DR. Noncontraceptive health benefits of oral steroidal contraceptives. American Journal of Obstetrics and Gynecology 142: 809–816, 1982PubMedGoogle Scholar
  38. Nilsson L, Rybo G. Treatment of menorrhagia. American Journal of Obstetrics and Gynecology 110: 713–720, 1971PubMedGoogle Scholar
  39. Rees MCP, Anderson AB, Demers LM, Turnbull AC. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea. British Journal of Obstetrics and Gynaecology 91: 673–680, 1984PubMedCrossRefGoogle Scholar
  40. Rees MCP, Canete-Soler R, Lopez Bernai A, Turnbull AC. Effects of fenamates on prostaglandin E receptor binding. Lancet 2: 541–542, 1988PubMedCrossRefGoogle Scholar
  41. Rees MCP, Di Marzo V, Tippins JR, Morris HR, Turnbull AC. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. Journal of Endocrinology 113: 291–295, 1987PubMedCrossRefGoogle Scholar
  42. Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology 91: 913–916, 1984PubMedCrossRefGoogle Scholar
  43. Smith SK, Abel MH, Kelly RW, Baird DT. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology 88: 434–442, 1981PubMedCrossRefGoogle Scholar
  44. Tauber PF, Kloppel A, Goodpasture JC, Burns J, Ludwig H, et al. Reduced menstrual blood loss by release of an antifibrolytic agent from intrauterine contraceptive devices. American Journal of Obstetrics and Gynaecology 140: 322–328, 1981Google Scholar
  45. Thiery M, Van der Pas H, Delbarge W, Van Kets H. The levonorgestrel intrauterine device. Geburtshilfe und Frauenheilk-und 49: 186–188, 1898CrossRefGoogle Scholar
  46. Treolar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. International Journal of Fertility 12: 77–126, 1967Google Scholar
  47. Vargyas JM, Campeau JD, Mishell Jr DR. Treatment of menorrhagia with meclofenamate sodium. American Journal of Obstetrics and Gynecology 157: 944–950, 1987PubMedGoogle Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Jennifer M. Higham
    • 1
  • Robert W. Shaw
    • 1
  1. 1.Department of Academic Obstetrics and GynaecologyRoyal Free HospitalLondonEngland

Personalised recommendations